Official UK procurement notice
Call for information/EOI for neutralising antibodies.
Authority: Department of Health & Social Care (Central government)
What is being bought
Published requirement descriptionDHSC invites suppliers to submit an EOI on neutralising antibodies andbinding site, clinical trials on efficacy, safetyfor preventing or treating COVID-19infection, dose&frequency, formats/routesfor administering to patients, monitoringadverse affects, efficacy against SARSCoV-2 variants, supply availability for 2021-2022 and future years and plans forregulatory approval in the UK, if not yetapproved.
CPV: Pharmaceutical products
The lotProcurement structure
single lot · no lot value publishedLot #1The Department is interested in engaging with the emerging market through expressions…Planned
The Department is interested in engaging with the emerging market through expressions of interest prior to the publication of a contract notice to findinnovative neutralising antibody COVID-19 therapies that could inform the specification of requirements,conditions of contract and commercial model. Further details of how suppliers may engage with the Departmentare included in section VI.3) (additional information) at the end of this notice. Additional information: Interested parties should submit questions via Atamis. Department welcomes discussions with interested parties on areas provision of a value for money solution for the UK tax payer;creating mechanisms for money solution for the UK tax payer;creating mechanisms (including but not limited to agreements) to secure long-term, guaranteed supply contracts with ‘step-in’ rights in future pandemics
Procedure terms & legal framework
From the official record · publisher note attached- Legal basis
- CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)
- Procurement category
- Goods
- Notice status
- Past planning notice
- Procurement threshold
- Unspecified in notice
- Regulatory regime
- Standard
- Commercial structure
- Stand-alone contract (no framework)
- Competition type
- Competitive procedure
- GPA / WTO covered
- Yes (GPA)
- Recurring procurement
- Unspecified in notice
- First published
- 5 Oct 2021, 16:37 BST
- Last source update
- 10 Dec 2021, 09:39 GMT
- FTS notice number
2021/S 000-030768- Classification (CPV)
- Delivery area
- Official registry OCID
ocds-h6vhtk-02e853Find a Tender
Publisher note: This Prior Information Notice has been issued to alert the market for the possible procurement of neutralising antibodies. Suppliers should submit expressions of interest.
How it was run
Official noticeTender documents are also served through a separate tool: http://health.atamis.co.uk ↗
- Submission deadline
- —
Timeline
10 Dec 2021 → 31 Mar 2022 · 2 dates- Notice published10 Dec 2021, 09:39 GMT
- Tender notice expected31 Mar 2022, 00:00 BST
Notice history
2 releases on Find a TenderPublished amendments (1 · 0 deadline changes)
| When | What | Before | After | Shift |
|---|---|---|---|---|
| — | TextShort description · II.1.4.1 | DHSC invites suppliers to submit an EOI on neutralising antibodies and binding site, clinical trials on efficacy, safety for preventing or treating COVID-19 infection, dose&frequency, formats/routes for administering to patients, monitoring adverse affects, efficacy against SARSCoV- 2 variants, supply availability for 2021- 2022 and future years and plans for regulatory approval in the UK, if not … | The Department of Health and Social Care is seeking to progress additional market engagement to identify neutralising antibodies or similar acting molecules, that are effective for treatment and prophylaxis, though passive immunisation, against SARS-CoV-2 for patients in hospital, or community setting. We would welcome specific information on the product's efficacy against SARS-CoV-2 variants, inc… | |
| — | TextDescription of procurement · II.2.4.1 | The Department is interested in engaging with the emerging market through expressions of interest prior to the publication of a contract notice to find innovative neutralising antibody COVID-19 therapies that could inform the specification of requirements, conditions of contract and commercial model. Further details of how suppliers may engage with the Department are included in section VI.3) (add… | The Therapeutics Taskforce is responsible for the end-to-end provision of treatments for COVID-19 in the UK, from the initial identification of potential therapeutics, to trialing treatments as part of an advanced programme of clinical trials, and their eventual deployment at scale to the patient population. These safe and effective treatments are vital for lessening the severity and impact of COV… |
This Prior Information Notice has been issued to alert the market for the possible procurement of neutralising antibodies. Suppliers should submit expressions of interest. Interested parties will be able to submit any questions regarding this PIN via Atamis. The Department welcomes discussions with interested parties on areas of interest including, (but not limited to): - provision of a value for …
Commercial outcome & contract awards
Pipeline notice- Awards (0)
- No award published
- Contracts (0)
- No contract published
- Bid statistics
- No aggregate bid statistics published
Contracting authority & participating public bodies
Official documents & specifications
Official links; attachments are not copiedNo document links were published on the notice.